Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre.

Abstract

Aim: To present efficacy and safety of 0.19 mg fluocinolone acetonide insert (FAi) to treat chronic noninfectious uveitis (NIU) in a single referral center.Methods: A retrospective observational clinical study of 11 eyes with NIU complicated by chronic cystoid macular edema (CMO).Results: The main indication for treatment was chronic CMO in all 11 eyes. The mean central retinal thickness (CRT) at baseline was 435\xa0μm ± 176, improving to 296\xa0μm ± 67 at 12\xa0months. Raised intraocular pressure (IOP) was the commonest adverse event. An IOP >21\xa0mmHg was observed in three eyes, and >30\xa0mmHg in one eye, managed with topical therapy. The mean best corrected visual acuity (BCVA) was stable at 12\xa0months. There were no observed recurrences of uveitis. Two eyes received adjunctive treatment for worsening CRT.Conclusions: Our results suggest FAi is an effective maintenance treatment for NIU with favorable functional and anatomical outcomes.